Top Medical News
Ertapenem infusion beneficial in hidradenitis suppurativa
10 hours ago
Treatment with intravenous ertapenem yields improvements in the clinical and inflammatory markers of hidradenitis suppurativa (HS), according to a retrospective study.
LDL-C–lowering therapies bear a small risk of haemorrhagic stroke
Jairia Dela Cruz, 14 hours ago
Medications that regulate low‐density lipoprotein‐cholesterol (LDL‐C) levels appear to contribute to a slight increase in the risk of haemorrhagic stroke events, according to a meta-analysis.
Pembrolizumab delivers long-term survival benefits in advanced esophageal cancer
Stephen Padilla, 16 hours ago
First-line pembrolizumab (pembro) plus chemotherapy (chemo) in patients with untreated advanced esophageal cancer demonstrates robust efficacy after 5 years, with no new safety concerns, when compared with placebo plus chemo, according to a study presented at ASCO GI 2024.
Methylnaltrexone proves safety in paediatric oncology patients with constipation
17 hours ago
Subcutaneous methylnaltrexone is safe to use in children with cancer who have opioid-induced constipation, suggest the results of a study. In addition, this agent stimulates bowel movements in more than a third of paediatric patients.
Eye diseases spell increased risk of falls, fractures
22 hours ago
People with cataract, age-related macular degeneration (AMD), and/or glaucoma are at heightened risk of both falls or fractures, as shown in a study.
Severe OSA increases nocturnal AF risk in patients with ischaemic heart disease
Elaine Soliven, Yesterday

Among patients with ischaemic heart disease (IHD), the presence of severe obstructive sleep apnoea (OSA) was associated with an increased risk of atrial fibrillation (AF) during sleep, according to a recent study in Singapore.

Does hand grip strength correlate with clinical disease activity in CD?
Audrey Abella, Yesterday
Hand grip may be associated with clinical disease activity in patients with Crohn’s disease (CD), but hand grip measurements alone may not be the best predictor of disease activity or related disability, suggests a study presented at Crohn’s and Colitis Congress 2024.
Special Reports
COVID-19, influenza, death, hospital admission, adverse outcome
07 Feb 2024
A comparative analysis has shown that COVID-19 is distinctly more severe than seasonal influenza, with significantly increased long-term risks of adverse health outcomes and burdens.1
fenofibrate, metabolic syndrome, statins, omega-3 fatty acids, MACE
05 Feb 2024
A nationwide population-based cohort study in South Korea compared the effectiveness of omega-3 fatty acids and fenofibrate for reducing major adverse cardiovascular events (MACE) in individuals with metabolic syndrome (≥30 years) on statin therapy.1
Treating type 2 diabetes mellitus with G.R.A.C.E.
22 Jan 2024
A challenging aspect of glycaemic control presents in patients diagnosed with early-onset type 2 diabetes mellitus (T2DM). Considering this challenge, how can effective management of glycaemic control be achieved in patients with uncontrolled T2DM who are hesitant to incorporate multiple oral antidiabetic drugs into their current regimen? In this case study, Dr Matthew Tan shared his clinical experience in managing a young adult patient with T2DM using GLYXAMBI®, a fixed-dose combination of empagliflozin and linagliptin taken once daily. He demonstrated how applying the G.R.A.C.E. concept to the treatment improved the patient’s clinical outcome.

This advertorial is sponsored as an educational programme by Boehringer Ingelheim Singapore Pte. Ltd.
Effectiveness of mRNA Vaccines Against Omicron XBB Infection in Singaporean Children Under 5: A Population-Based Cohort Study
22 Jan 2024
Limited data exists on COVID-19 mRNA vaccine effectiveness in children aged 1–4 years, particularly against Omicron subvariants. In a cohort study conducted during Omicron XBB subvariant predominant period in Singapore, completing the primary COVID-19 mRNA vaccine series significantly protected against COVID-19 infection in this age group, with 45.2% and 63.3% vaccine effectiveness in partially and fully vaccinated children, respectively. Vaccine effectiveness was also robust at 74.6% in children with prior COVID-19 infection who received at least one vaccine dose.
Nicorette® QuickMist Launch Symposium
19 Jan 2024
During the launch of Nicorette® QuickMist at the Kuala Lumpur Nicotine Addiction International Conference (KLNAC) 2023, a panel of distinguished experts led the discussion on the role of Nicotine Replacement Therapy (NRT) on smoking cessation management. The panel comprised of notable experts, including Professor Chris Bullen (New Zealand), Associate Professor Dr Amer Siddiq bin Amer Nordin (Malaysia), Dr Philip Tønnesen (Denmark) and Professor Philip Eng (Singapore).
COVID-19, nirmatrelvir, ritonavir, mRNA vaccine, Omicron, COPD, CDC, WHO
Dr. Chan Kwok Wai Adrian, Prof. Yang Kuang-Yao, 10 Jan 2024
At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.
Navigating invasive fungal infections in unconventional hosts — insights and strategies
Assoc Prof. Carolina García-Vidal, Dr. Jasmine Chung, 06 Jan 2024

At a recent symposium organized by Pfizer, in collaboration with the Society of Infectious Disease Singapore, A/Prof Carolina García-Vidal, Senior Specialist, Infectious Diseases Department at Hospital Clínic de Barcelona, Spain, shared valuable insights on managing invasive fungal infections (IFIs) in nontraditional hosts. The session was chaired by Dr Jasmine Chung, Senior Consultant and Director of the Antimicrobial Stewardship Unit, Singapore General Hospital.

Conference Reports
Does hand grip strength correlate with clinical disease activity in CD?
Audrey Abella, 23 Feb 2024
Hand grip may be associated with clinical disease activity in patients with Crohn’s disease (CD), but hand grip measurements alone may not be the best predictor of disease activity or related disability, suggests a study presented at Crohn’s and Colitis Congress 2024.
Thoracoscopic esophagectomy better than open surgery in esophageal cancer
Stephen Padilla, 23 Feb 2024
Thoracoscopic esophagectomy (TE) has demonstrated its noninferiority to open transthoracic esophagectomy (OE) for patients with thoracic esophageal cancer in a study presented at ASCO GI 2024.
Maternal transplacental transfer of nipocalimab negligible in foetuses, neonates
Audrey Abella, 23 Feb 2024
In the phase II UNITY study, foetuses and neonates whose mums were receiving nipocalimab for early-onset (≤24 weeks gestational age [GA]) severe haemolytic disease of the foetus and newborn (EOS-HDFN) had minimal exposure to the drug.
Dementia risk threefold higher in the first year after a stroke
Elaine Soliven, 23 Feb 2024

Stroke survivors were more likely to develop dementia within the first year following their stroke than the general population and people with acute myocardial infarction (MI), according to a study presented at ISC 2024.

Infliximab, vedolizumab similarly effective as 1L Tx for paediatric IBD
Audrey Abella, 22 Feb 2024
In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achiev­ing steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with un­complicated mild-to-moderately active inflammatory bowel disease (IBD).
Reteplase a good alternative to alteplase in acute ischaemic stroke
Stephen Padilla, 20 Feb 2024
Treatment with reteplase appears more effective than alteplase in patients with acute ischaemic stroke (AIS) who have been treated within 4.5 hours of symptom onset, according to the results of RAISE, a phase III multicentre, open-label, randomized controlled, noninferiority trial.
Earlier anticoagulation reversal tied to improved survival in ICH patients
Audrey Abella, 20 Feb 2024
In anticoagulation-associated intracerebral haemorrhage (ICH), earlier administration of reversal treatments is associated with reduced in-hospital mortality or discharge to hospice, according to data presented at ISC 2024.